Angela VollstedtDirector, Cell & Gene Therapies Portfolio Management at NovartisSpeaker
Profile
A microbiologist and biochemist by training from the University of Cambridge, UK, Angela holds a PhD in bacterial secretory protein production from the Research Center Juelich, Germany. After more than 15 years in biopharmaceutical development and strategic business development at Sandoz and Novartis, she joined Novartis Cell & Gene Therapies Portfolio Management to advance the field of autologous CAR-T cell therapy development using innovative expansionless CAR-T manufacturing technology. In this role, she led the novel CAR-T manufacturing roll-out into clinical development and advanced multiple early-stage CAR-T programs leveraging T-Charge platform technology.
Agenda Sessions
Chair’s Welcome Remarks: Cell and Gene Therapy Manufacturing
, 10:55View SessionChairperson Remarks: Cell and Gene Therapy Manufacturing
, 13:55View Session